Introduction {#Sec1}
============

It is generally agreed that decreased insulin sensitivity is an important component in the pathogenesis of obesity, type 2 diabetes, hyperuricemia, cardiovascular disease, hypertension and polycystic ovary syndrome \[[@CR1], [@CR2]\]. Insulin resistance might be associated with an impaired ability of insulin to stimulate glucose oxidation and inhibit lipid oxidation \[[@CR3]--[@CR5]\]. It might also be related to an impaired insulin-stimulated non-oxidative glucose metabolism (NOGM), which reflects the rate of glycogen synthesis, mainly in the skeletal muscle \[[@CR6]--[@CR8]\]. The balance between various cytokines plays an important role in modeling insulin action, which is inversely associated with circulating pro-inflammatory cytokines like TNF-α \[[@CR9]--[@CR14]\] and positively related to anti-inflammatory adipocytokines like adiponectin \[[@CR15]--[@CR19]\]. Adiponectin has protective effects against cardiovascular disease (CVD) \[[@CR20]\]. Sheng-Chiang Su et al. recently showed that adiponectin was significantly correlated with HOMA-IR and BMI might be the major determinant of plasma adiponectin and pro-inflammatory cytokines in young diabetes mellitus patients \[[@CR20]\].

Adiponectin and TNF-α could modulate the rates of substrates' metabolism. There is evidence that adiponectin has insulin-sensitizing properties \[[@CR16], [@CR18], [@CR21]\] and could be involved in glucose and lipid metabolism \[[@CR5], [@CR8], [@CR22], [@CR23]\]. It is less clear whether adiponectin is associated more with oxidative glucose or lipid metabolism during hyperinsulinemia \[[@CR5], [@CR22], [@CR24], [@CR25]\] or NOGM \[[@CR8], [@CR21], [@CR22], [@CR24], [@CR26]\]. In experimental studies, recombinant adiponectin improved insulin sensitivity, mainly by increasing fatty acid oxidation \[[@CR23]\]. Yin et al. showed that adiponectin can suppress lipid accumulation by promoting fatty acid oxidation during C2C12 myogenesis, rather than fatty acid hydrolysis and synthesis \[[@CR27]\]. Decreased adiponectin level is associated with decreased insulin-stimulated glucose uptake and oxidation \[[@CR28]\].

Serum levels of soluble TNF-α receptors (sTNFR1 and sTNFR2) are supposed to reflect local tissue action of this cytokine \[[@CR10], [@CR29]\]. There are conflicting data regarding the role of TNF-α in the control of substrate utilization. TNF-α-stimulated lipolysis was accompanied by decrease in fatty acid oxidation in 3T3-L1 adipocytes \[[@CR30]\]. Pellieux et al. showed that angiotensin II decreased fatty acid oxidation pathway in adult rat cardiomyocytes by generation of TNF-α \[[@CR31]\]. On the other hand, new data showed that TNFRs play a physiological role to limit body weight and adiposity by modestly increasing metabolic rate and fatty acid oxidation, and they alter adipose tissue macrophages status \[[@CR32]\]. Plomgaard et al. demonstrate that 4-h rhTNF-α infusion increases whole-body lipolysis, without enhancing skeletal muscle fat metabolism and without affecting basal glucose turnover \[[@CR33]\]. However, data in a human cardiac cell model demonstrated that TNF-α reduces the expression of PGC-1α (peroxisome proliferator--activated receptor coactivator 1 α) which resulted in an increase in glucose oxidation rate \[[@CR34]\].

Precise measurement of insulin sensitivity is an important issue, and different methods are proposed \[[@CR36]\]. There are also simple indices of insulin action, for instance IGFBs (insulin-like growth factor--binding proteins) \[[@CR37]\]. However, euglycemic hyperinsulinemic clamp remains the "gold standard" in assessing insulin sensitivity in vivo.

The aim of the present study was to analyze the associations between serum adiponectin, sTNFR1 and sTNFR2 concentrations and the whole-body insulin sensitivity, lipid and glucose oxidation and NOGM by applying the euglycemic clamp technique and indirect calorimetry in lean and obese subjects.

Methods and procedures {#Sec2}
======================

We examined 53 subjects: 25 lean (BMI \< 25 kg × m^−2^) and 12 subjects with overweight (25 kg × m^−2^\>BMI \< 30 kg × m^−2^) (3 men and 9 women) and 16 subjects with obesity (BMI \> 30 kg × m^−2^) (3 men and 13 women). We actively recruited the subjects to participate in the study. Obese subjects were partly recruited from the Outpatient Clinic of the Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok. Additionally, overweight/obese and control subjects were recruited from the medical staff and students. All participants had no morbid obesity, cardiovascular disease, hypertension, infections and any other serious medical problems and were not taking anti-inflammatory drugs (within previous 3 months) or any drugs known to affect glucose and lipid metabolism. Before entering the study, physical examination was performed. All subjects underwent an oral glucose tolerance test (OGTT) and had normal glucose tolerance according to WHO criteria. All subjects gave written informed consent before entering the study. The study protocol was approved by the Ethics Committee of Medical University of Bialystok, Poland.

Anthropometric measurements {#Sec3}
---------------------------

BMI was calculated as body weight in kilograms divided by height in meters squared (kg/m^2^). The waist circumference was measured at the smallest circumference between the rib cage and the iliac crest, with the subject in the standing position. Percent of body fat was estimated by bioelectric impedance analysis using the Tanita TBF-511 Body Fat Analyzer (Tanita Corp., Tokyo, Japan).

Insulin sensitivity {#Sec4}
-------------------

Insulin sensitivity was evaluated by the euglycemic hyperinsulinemic clamp technique as described by DeFronzo et al. \[[@CR35]\]. Insulin (Actrapid HM, Novo Nordisk, Copenhagen, Denmark) was given as a primed continuous intravenous infusion for 2 h at 40 mU × m^−2^ × min^−1^, resulting in constant hyperinsulinemia of approximately 75 mU/l. Arterialized blood glucose was obtained every 5 min, and 20% dextrose (1.11 mol/l) infusion was adjusted to maintain plasma glucose levels at 5.0 mmol/l. The glucose infusion rate approached stable values during final 40 min of the study, and the rate of whole-body glucose uptake (*M* value) was calculated as the mean glucose infusion rate from 80 to 120 min, corrected for glucose space and normalized per kilogram of fat-free mass (*M*~ffm~).

Lipid and glucose oxidation {#Sec5}
---------------------------

Whole-body lipid and glucose oxidation rates were measured by indirect calorimetry using the ventilated hood technique (Oxycon Pro, Viasys Healthcare GmbH---Erich Jaeger, Hochberg, Germany) in order to calculate lipid and glucose oxidation from respiratory gas exchange (oxygen consumption and carbon dioxide production). The device was calibrated before each test using reference gases. Measurements were taken while the subjects were lying in a supine position at baseline (in the fasting state) and during the last 30 min of the clamp study. Each study was performed in the thermoneutral environment, after relaxing for 15 min. NOGM was calculated by subtracting the glucose oxidation rate during hyperinsulinemia from whole-body glucose disposal rate. An increase in respiratory exchange ratio (detla RER) in response to insulin was used as a measure metabolic flexibility.

Biochemical analyses {#Sec6}
--------------------

Fasting blood samples were taken from the antecubital vein before the beginning of the clamp for the determination of serum lipids, sTNFR1, sTNFR2 and adiponectin concentrations. Samples were frozen at −70°C until analyses. Plasma glucose was measured immediately by the enzymatic method using glucose analyzer (YSI 2300 STAT PLUS). Serum insulin was measured with the Medgenix EASIA test (BioSource Europe, Nivelles, Belgium). The minimum detectable concentration was 1.05 pg/l, and the intra-assay and inter-assay coefficients of variation (CVs) were below 5.5 and 10%, respectively. In that method, human and animal proinsulins present no cross-reaction. Serum total and HDL cholesterol and triglycerides (TG) were assessed by the enzymatic methods using commercial kits produced by ANALCO-GBG, Poland. Concentration of LDL cholesterol (LDL-CH) was calculated from Friedewald's formula: LDL-CH = total cholesterol − TG/5 − HDL cholesterol (mg/dl).

Serum sTNFR1 and sTNFR2 were determined with the EASIA kits (BioSource Europe). The minimum detectable concentration was 0.05 ng/ml for sTNFR1 and 0.1 ng/ml for sTNFR2. The intra-assay and inter-assay CVs for both receptors were below 6.5 and 9%, respectively. sTNFR1 EASIA does not cross-react with sTNFR2. Serum adiponectin was measured with the RIA Kit (Linco Research, Inc. St. Charles, Missouri, USA) with the detection limit of 1 ng/ml and with intra-assay and inter-assay CVs below 6.3 and 9.5%, respectively.

Statistical analysis {#Sec7}
--------------------

The statistics were performed with the STATISTICA 8.0 program (StatSoft, Krakow, Poland). The variables that did not have normal distribution were log-transformed prior to analyses (TG, insulin). The differences between the groups were evaluated with one-way ANOVA and with post hoc Tukey's honestly significant difference test for unequal sample sizes. When overweight and obese subjects were pooled together, the differences between the groups were evaluated with an unpaired Student's *t* test. The relationships between variables were estimated with the simple and multiple regression analysis. The level of significance was accepted at *P* value less than 0.05.

We calculated the sample size on the basis of our previous data on insulin sensitivity (but without indirect calorimetry), serum adiponectin, sTNFR1 and sTNFR2, obtained on the population of about 300 subjects, with similar characteristics to the study group included in the present paper. The results of all these parameters were very similar in these groups. On that basis, the minimal sample size in each group to detect significant differences at α \< 0.05 and 1 − β \> 0.80 was *n* = 22 for insulin sensitivity; *n* = 20 for serum adiponectin; *n* = 16 for sTNFR1; and *n* = 21 for sTNFR2.

Results {#Sec8}
=======

The clinical characteristics of the studied groups are shown in Table [1](#Tab1){ref-type="table"}. Obese subjects had lower insulin sensitivity and serum adiponectin concentration (*P* = 0.003 and *P* = 0.007, respectively) versus lean subject. Serum levels of sTNFR1 and sTNFR2 were higher in the obese group (*P* \< 0.001 and *P* = 0.008, respectively) versus lean group (Table [1](#Tab1){ref-type="table"}).Table 1Clinical and biochemical characteristics of the studied groupsLean subjects (*n* = 25)Overweight subjects (*n* = 12)Obese subjects (*n* = 16)*P*Age (year)25.1 ± 5.325 ± 5.328.3 ± 7.90.23M/F6/193/93/13BMI (kg/m^2^)21.64 ± 2.0327.11 ± 1.7733.89 ± 2.96\<0.0001Waist girth (cm)74.2 ± 6.185.3 ± 5.9\*,\*\*\*104.1 ± 6.9\*\*\<0.0001Body fat (%)23.2 ± 6.630.4 ± 7.5\*\*\*42.9 ± 10.7\*\*\<0.0001Total cholesterol (mg/dl)172.7 ± 31.2176.2 ± 39.2176.9 ± 40.20.92Serum TG (mg/dl)71.3 ± 32.885.0 ± 32.3179.0 ± 226.2\*\*0.03HDL cholesterol (mg/dl)60.3 ± 10.556.1 ± 6.254.4 ± 9.40.13LDL cholesterol (mg/dl)98.1 ± 31.398.5 ± 34.188.0 ± 23.80.58Fasting glucose (mg/dl)80.4 ± 7.484.3 ± 6.883.4 ± 9.60.29Postload glucose (mg/dl)75.3 ± 15.887.8 ± 16.196.2 ± 21.8\*\*0.002Fasting insulin (μIU/ml)11.9 ± 5.212.4 ± 4.1\*\*\*22.3 ± 13.4\*\*0.001Postload insulin (μIU/ml)30.9 ± 19.047.7 ± 36.395.4 ± 78.2\*\*\<0.0001*M* (mg × kg~ffm~^−1^ × min^−1^)11.16 ± 3.079.01 ± 2.617.21 ± 3.95\*\*0.001Serum adiponectin (μg/ml)16.2 ± 4.712.1 ± 5.411.2 ± 3.2\*\*0.001Serum sTNFR1 (ng/ml)1.78 ± 0.292.02 ± 0.292.27 ± 0.35\*\*\<0.0001Serum sTNFR2 (ng/ml)3.80 ± 0.884.46 ± 0.894.86 ± 0.91\*\*0.002Data are presented as mean ± SD*M/F* Male/female, *BMI* Body mass index, *OGTT* Oral glucose tolerance test, *M* Whole-body glucose uptake normalized per kg of fat-free mass, *sTNFR1* Soluble TNFα receptor 1, *sTNFR2* Soluble TNFα receptor 2\* *P* \< 0.05 in overweight versus lean subjects\*\* *P* \< 0.05 in obese versus lean subjects\*\*\* *P* \< 0.05 in overweight versus obese subjects

Fasting rates of lipid and glucose oxidation did not differ between studied groups. Obese subject had higher rate of lipid oxidation during the clamp (*P* = 0.003) and lower NOGM and metabolic flexibility (both *P* = 0.01) versus lean group (Table [2](#Tab2){ref-type="table"}).Table 2Respiratory exchange ratio, nutrient oxidation rate, NOGM and metabolic flexibility before and during clamp in lean and obese subjectsLean subjects (*n* = 25)Overweight subjects (*n* = 12)Obese subjects (*n* = 16)*P*RER-basal0.80 ± 0040.80 ± 0.040.82 ± 0.060.63RER-clamp0.86 ± 0.040.82 ± 0.050.81 ± 0.04\*0.01COx-basal (mg × kg~ffm~^−1^ × min^−1^)1.35 ± 0.771.32 ± 0.681.81 ± 1.180.21LOx-basal (mg × kg~ffm~^−1^ × min^−1^)1.03 ± 0.351.12 ± 0.321.19 ± 0.600.47COx-clamp (mg × kg~ffm~^−1^ × min^−1^)2.32 ± 0.861.76 ± 0.821.66 ± 0.850.03LOx-clamp (mg × kg~ffm~^−1^ × min^−1^)0.69 ± 0.360.99 ± 0.381.18 ± 0.45\*0.001NOGM (mg × kg~ffm~^−1^ × min^−1^)8.84 ± 3.07.25 ± 2.355.55 ± 3.75\*0.007Delta RER0.05 ± 0.050.02 ± 0.05−0.004 ± 0.05\*0.006Data are presented as mean ± SD*RER1* Respiratory exchange ratio before clamp, *RER2* Respiratory exchange ratio during clamp, *REE1* Resting energy expenditure before clamp, *REE2* Resting energy expenditure during clamp, *COx-basal* Rate of glucose oxidation in the basal state, *LOx-basal* Rate of lipid oxidation in the basal state, *COx-clamp* Rate of glucose oxidation during hyperinsulinemia, *LOx-clamp* Rate of lipid oxidation during hyperinsulinemia, *NOGM* Non-oxidative glucose metabolism, *delta RER* Change in respiratory exchange ratio in response to hyperinsulinemia\* *P* \< 0.05 in obese versus lean subjects

Additionally, because there were no differences between overweight and obese subjects in insulin sensitivity, serum adiponectin, sTNFR1 and sTNFR2, we calculated data for overweight and obese subjects pooled together. The results of the research showed that obese/overweight subjects had lower insulin sensitivity and serum adiponectin concentration (both *P* \< 0.001). Serum levels of sTNFR1 and sTNFR2 were higher in these group (*P* \< 0.001 and *P* = 0.001, respectively).

Fasting rates of lipid and glucose oxidation also did not differ between lean and obese/overweight groups. Obese/overweight group had higher rate of lipid oxidation during the clamp (*P* = 0.0005) and lower rate of glucose oxidation during hyperinsulinemia (*P* = 0.01), lower NOGM and metabolic flexibility (*P* = 0.004 and *P* = 0.003, respectively).

Insulin sensitivity was positively related to serum adiponectin concentration (*r* = 0.49, *P* \< 0.001) and negatively related to sTNFR1 and sTNFR2 (*r* = −0.40, *P* = 0.004, *r* = −0.52, *P* \< 0.001, respectively). Adiponectin was related to the rate of glucose (*r* = 0.47, *P* \< 0.001) and lipid (*r* = −0.40, *P* = 0.003) oxidation during the clamp (Fig. [1](#Fig1){ref-type="fig"}a, b). We also found positive correlation between adiponectin and RER during the clamp (*r* = 0.43, *P* = 0.001) and with NOGM (*r* = 0.41, *P* = 0.002) and metabolic flexibility (*r* = 0.36, *P* = 0.007). Serum sTNFR1 concentration was associated with the rate of glucose (*r* = −0.45, *P* = 0.001) (Fig. [1](#Fig1){ref-type="fig"}c) and lipid (*r* = 0.52, *P* \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}d) oxidation during hyperinsulinemia and also with NOGM (*r* = −0.31, *P* = 0.02) and metabolic flexibility (*r* = −0.47, *P* \< 0.001). Similarly, serum sTNFR2 correlated with the rate of glucose (*r* = −0.51, *P* \< 0.001) and lipid (*r* = 0.46, *P* = 0.001) oxidation and with NOGM (*r* = −0.43, *P* = 0.002) and metabolic flexibility (*r* = −0.51, *P* \< 0.001).Fig. 1Relationship between serum adiponectin and glucose oxidation (**a**) and lipid oxidation (**b**) during hyperinsulinemia and relationship between serum sTNFR1 and glucose oxidation (**c**) and lipid oxidation (**d**) during the clamp in the entire study group (*n* = 53)

We observed negative correlation between waist circumference and adiponectin (*r* = −0.39, *P* = 0.003) and positive correlation between waist circumference and sTNFR1 and sTNFR2 (*r* = 0.58, *P* \< 0.0001; *r* = 0.50, *P* \< 0.0001, respectively).

In multiple regression analysis, we observed that the relationship between M and adiponectin (β = 0.31; *P* = 0.02) was independent of age, gender and waist circumference (Table [3](#Tab3){ref-type="table"}). We observed also that the relationships between glucose oxidation during the clamp and sTNFR1 (β = −0.34; *P* = 0.03) and adiponectin (β = 0.38; *P* = 0.004) were independent of each other and also independent of age, gender and waist circumference (Table [4](#Tab4){ref-type="table"}). Similar results were obtained when sTNFR2 was entered instead of sTNFR1 into the regression model (adiponectin, β = 0.30, *P* = 0.02; sTNFR2, β = −0.48; *P* = 0.004) (Table [4](#Tab4){ref-type="table"}). Correlations between lipid oxidation during the clamp and sTNFR1 (β = 0.41; *P* = 0.008) (Table [4](#Tab4){ref-type="table"}) and sTNFR2 (β = 0.41; *P* = 0.01) (Table [5](#Tab5){ref-type="table"}) were independent of adiponectin, age and waist circumference.Table 3Multiple regression analysis of insulin sensitivity (*M*) and age, gender, WC and adiponectinVariable*MBP* valueAge−0.0960.411Gender0.2030.082WC−0.3430.009Adiponectin0.3120.016*WC* Waist circumference, *M* Whole-body glucose uptake normalized per kg of fat-free massTable 4Multiple regression analysis of lipid and glucose oxidation during the metabolic clamp and age, gender, WC, adiponectin and sTNFR1VariableLOx-clampCOx-clamp*BP* value*BP* valueAge0.00090.993−0.0580.635Gender0.2640.037−0.2060.111WC0.1540.324−0.0440.781Adiponectin−0.2460.0550.3880.004sTNFR10.4160.008−0.3460.031WC Waist circumference, *sTNFR1* Soluble TNFα receptor 1, *COx-clamp* Rate of glucose oxidation during hyperinsulinemia, *LOx-clamp* Rate of lipid oxidation during hyperinsulinemiaTable 5Multiple regression analysis of lipid and glucose oxidation during the metabolic clamp and age, gender, WC, adiponectin and sTNFR2VariableLOx-clampCOx-clamp*BP* value*BP* valueAge−0.0580.6290.0040.968Gender0.3150.027−0.3070.028WC0.2390.119−0.0670.652Adiponectin−0.1780.1850.2970.027sTNFR20.4060.018−0.4840.004WC Waist circumference, *sTNFR2* Soluble TNFα receptor 2, *COx-clamp* Rate of glucose oxidation during hyperinsulinemia, *LOx-clamp* Rate of lipid oxidation during hyperinsulinemia

Discussion {#Sec9}
==========

In the present study, we investigated serum adiponectin, sTNFR1 and sTNFR2 concentrations in relation to lipid and glucose metabolism. We showed decreased serum adiponectin concentration in obese patients and positive correlation between this cytokine and insulin sensitivity. There is growing evidence that adiponectin function is closely related to the pathogenesis of insulin resistance \[[@CR11], [@CR16]--[@CR18], [@CR21], [@CR39], [@CR40]\]. In our study, serum adiponectin concentration was negatively correlated with the rate of lipid oxidation during hyperinsulinemia and positively with NOGM and the rate of glucose oxidation during the clamp. These results suggest that high serum adiponectin concentration protects from developing insulin resistance by stimulating glucose oxidation and inhibiting lipid oxidation during hyperinsulinemia and increasing NOGM. These data are in agreement with Salmenniemi et al. who reported similar results in offspring of type 2 diabetic patients \[[@CR24]\]. Another group reported no significant correlation between serum adiponectin level and substrates oxidation, either before or during the clamp \[[@CR8]\]. However, these data were obtained mostly from type 2 diabetic subjects, older than in the present study. Højlund et al. showed that reduced serum adiponectin concentration may contribute to an impaired insulin activation of glycogen synthase in the skeletal muscle of patients with type 2 diabetes \[[@CR21]\]. It was also reported that adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle \[[@CR25]\] presumably via activation of AMP kinase \[[@CR23], [@CR25]\].

Another factors that could modulate insulin sensitivity and substrates metabolism are soluble TNF-α receptors. In the present report, we showed an increase in serum sTNFR1 and sTNFR2 concentration in obese patients in comparison with the lean subjects. We also observed negative correlation between insulin sensitivity and serum sTNFR1 and sTNFR2 concentrations. These findings are consistent with our previous reports \[[@CR11], [@CR13], [@CR38]\]. Our data indicate that a soluble TNF-α receptors are associated with insulin resistance through its relationship with substrate oxidation in hyperinsulinemic condition and NOGM. Hotamisligil et al. reported that TNF-α is an important mediator of insulin resistance in obesity through its ability to decrease the tyrosine kinase activity of the insulin receptor \[[@CR41]\]. TNF-α has been shown to inhibit insulin-stimulated GLUT4 translocation and glucose uptake through inhibition of insulin signaling \[[@CR9]\]. In experimental study, Bruce et al. showed that TNF-α had no effect on lipid oxidation but increased fatty acid incorporation into DAG, which may be involved in the development of TNF-α-induced insulin resistance in skeletal muscle \[[@CR42]\].

Although there are studies reporting the impact of TNF-α system on substrate oxidation, to the best of our knowledge, this is the first data to report such associations in human studies in vivo. Additionally, as mentioned in the Introduction, the human data regarding the association between adiponectin and substrate oxidation are controversial and our study provides the first results in this field obtained in young and apparently healthy population, free of potential multiple confounding factors.

The possible limitations of our study include relatively small number of male subjects, which can affect the results of gender and also limited number of subjects in overweight and obese groups. However, we were able to detect significant differences in insulin sensitivity and inflammatory markers between the groups when the overweight/obese subjects were pooled together and also between lean and obese subjects in one-way ANOVA with post hoc Tukey's test. Additionally, in the regression models, we observed that some of the relationships between inflammatory markers and substrate oxidation were independent of age and the measure of visceral adiposity (waist circumference).

Our data showed that soluble TNF-α receptors and adiponectin correlated in inverse manner with insulin sensitivity and they have multiple effect on substrates metabolism during hyperinsulinemia, NOGM and metabolic flexibility.

The obtained results suggest that soluble TNF-α receptors and adiponectin have multiple effects on glucose and lipid metabolism in obesity.
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